On October 4, SAS Cemag Invest declared to the AMF that it had exceeded the thresholds of 10% and 15% of Advicenne's capital and voting rights, to hold 18.00% of this biopharmaceutical company's capital and 17.56% of its voting rights.

This threshold crossing resulted from the subscription to a capital increase. Cemag Invest declares that it has no intention of continuing its purchases and acquiring control of Advicenne, nor of requesting the appointment of a new director.

Copyright (c) 2023 CercleFinance.com. All rights reserved.